XDH and chronic kidney disease: Regarding CKD development, compared with the nonusers, the users of XO inhibitors had an adjusted HR of 1.07 (95% CI: 0.93-1.22), and the users of uricosuric agents had an adjusted HR of 0.93 (95% CI: 0.83-1.04).